Clinical Trials

HER2-positive Metastatic Breast Cancer

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Breast Neoplasms

NCT04572295 2026-03-11

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

51 enrolled

Acrocephalosyndactylia, Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Breast Neoplasms, Recurrence

NCT05501886 2026-02-10

VIKTORIA-1

701 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT05646862 2026-02-05

INAVO121

420 enrolled

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT04305496 2026-01-29

CAPItello-291

818 enrolled 19 charts 2 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05365178 2026-01-07

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

432 enrolled

HR-positive, HER2-negative Breast Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

BreastGastrointestinalGenitourinaryGynecologicThoracic

217 enrolled 19 charts

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT04556773 2025-12-17

DB-08

138 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT04214288 2025-11-20

SERENA-2

240 enrolled 16 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT04557449 2025-10-01

CDK4i

BreastGastrointestinalGenitourinarySarcomaThoracic

362 enrolled

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06253195 2025-06-05

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

33 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05251714 2025-05-18

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

44 enrolled

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

78 enrolled

Breast Neoplasms

NCT05077449 2024-05-24

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

300 enrolled